目的 探討心通口服液聯(lián)合吲哚布芬治療冠心病心絞痛的臨床療效。方法 選取2023年5月—2024年10月在河北中石油中心醫(yī)院治療的冠心病心絞痛患者122例，按隨機(jī)數(shù)字表法將患者分為對(duì)照組和治療組，每組各61例。對(duì)照組口服吲哚布芬片，0.1 g/次，2次/d。在對(duì)照組基礎(chǔ)上，治療組飯后口服心通口服液，10 mL/次，3次/d。兩組患者療程均為4周。觀察兩組患者臨床療效，比較治療前后兩組患者心絞痛發(fā)作次數(shù)、疼痛VAS評(píng)分、發(fā)作持續(xù)時(shí)間、心電圖ST-T改善率，血瘀證、臨床結(jié)局評(píng)價(jià)（CHD-PRO）和西雅圖心絞痛量表（SAQ）評(píng)分，及凝血酶時(shí)間（TT）、國際標(biāo)準(zhǔn)化比值（INR）、血小板聚集率（PAR）、D-二聚體（D-D）和超敏-C反應(yīng)蛋白（hs-CRP）水平。結(jié)果 治療后，治療組總有效率為95.08%，明顯高于對(duì)照組（83.61%，P＜0.05）。治療后，兩組心絞痛發(fā)作次數(shù)、疼痛VAS評(píng)分、發(fā)作持續(xù)時(shí)間均低于組內(nèi)治療前（P＜0.05），且治療組明顯低于對(duì)照組（P＜0.05）。治療后，治療組心電圖ST-T改善率（85.25%）明顯高于對(duì)照組（70.49%，P＜0.05）。治療后，兩組患者血瘀證評(píng)分都低于組內(nèi)治療前，而CHD-PRO、SAQ評(píng)分高于治療前（P＜0.05），且治療后治療組各評(píng)分明顯好于對(duì)照組（P＜0.05）。治療后，兩組TT、INR均高于組內(nèi)治療前，而PAR和血漿D-D、hs-CRP水平都低于組內(nèi)治療前（P＜0.05），且治療組凝血指標(biāo)、PAR和血漿D-D、hs-CRP水平明顯好于對(duì)照組（P＜0.05）。結(jié)論 針對(duì)冠心病心絞痛聯(lián)合使用心通口服液與吲哚布芬，安全性較好，能有效緩解患者心絞痛癥狀，改善血瘀狀態(tài)，提升全面健康狀況與生活質(zhì)量，并利于進(jìn)一步調(diào)節(jié)凝血功能，控制血栓形成和炎癥反應(yīng)。

Objective To explore the clinical efficacy of Xintong Oral Liquid combined with indobufen in treatment of angina pectoris in coronary heart disease. Methods Patients (122 cases) with angina pectoris in coronary heart disease in Hebei Petrochina Central Hospital from May 2023 to October 2024 were divided into control group and treatment group according to random number table method, with 61 cases in each group. Patients in the control group were po administered with Indobufen Tablets, 0.1 g/time, twice daily. Patients in the treatment group were po administered with Xintong Oral Liquid on the basis of the control group after meals, 10 mL/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical evaluations were evaluated, and the frequency of colic episodes, pain VAS score, duration of episodes, ECG ST-T improvement rate, blood stasis syndrome scores and CHD-PRO, SAQ scores, the levels of TT, INR, PAR, D-D and hs-CRP in two groups before and after treatment were compared. Results After treatment, the total effective rate of treatment group was 95.08%, significantly higher than that of control group (83.61%, P < 0.05). After treatment, angina attack frequency, pain VAS score and attack duration in two groups were lower than those before treatment (P < 0.05), and treatment group was significantly lower than that in control group (P < 0.05). After treatment, the improvement rate of ECG ST-T in treatment group (85.25%) was significantly higher than that in control group (70.49%, P < 0.05). After treatment, the scores of blood stasis syndrome in two groups were lower than those before treatment, while the scores of CHD-PRO and SAQ were higher than those before treatment (P < 0.05), and the scores of treatment group were significantly better than those of control group (P < 0.05). After treatment, TT and INR in two groups were higher than before treatment, while PAR and plasma D-D and hs-CRP levels were lower than before treatment in the group (P < 0.05). After treatment, the coagulation indicators, PAR and plasma D-D, hs-CRP levels in the treatment group were significantly better than those in the control group (P < 0.05). Conclusion Xintong Oral Liquid combined with indobufen in treatment of coronary heart disease angina pectoris is safe. It can effectively relieve patients' angina symptoms, improve blood stasis, improve overall health status and quality of life, and help to further regulate coagulation function and control thrombosis. and inflammatory response.

R972

廊坊市科技支撐計(jì)劃項(xiàng)目（2023013035）